Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14418732 | 0.95 | STAT3 (0.58) | STAT3HSD17B10GFERPOLBNPC1 | |
| SCHEMBL10851503 | 0.84 | STAT3 (0.51) | STAT3HSD17B10GFERPOLBTUBB4A | |
| SCHEMBL11709672 | 0.82 | STAT3 (0.56) | STAT3HSD17B10GFERPOLBTUBB4A | |
| SCHEMBL10850355 | 0.82 | STAT3 (0.53) | STAT3HSD17B10GFERPOLBTUBB4A | |
| SCHEMBL30897295 | 0.81 | STAT3 (0.58) | STAT3HSD17B10GFERPOLBNPC1 | |
| SCHEMBL11382070 | 0.81 | STAT3 (0.58) | STAT3HSD17B10GFERPOLBNPC1 | |
| SCHEMBL15935641 | 0.80 | STAT3 (0.53) | STAT3HSD17B10GFERPOLBTUBB4A | |
| SCHEMBL11707646 | 0.78 | GFER (0.50) | STAT3HSD17B10GFERPOLBTUBB4A | |
| SCHEMBL9514779 | 0.78 | STAT3 (0.59) | STAT3HSD17B10GFERPOLBTUBB4A | |
| SCHEMBL10854182 | 0.78 | MAPT (0.56) | STAT3HSD17B10GFERPOLBTUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008340-B2 | 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase I | AVENTIS PHARMACEUTICALS INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1791537-B1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMA INC (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-21 | — | — | US | disclosed |
| EP-1915055-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070142454-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1791537-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2007021629-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006041961-A1 | ARYLTHIOINDOLE TUBULIN POLYMERIZATION INHIBITORS AND METHODS OF TREATING OR PREVENTING CANCER USING SAME | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006023590-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-0790993-A1 | NONPEPTIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015125-A1 | NONPEPTIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5482960-A | Nonpeptide endothelin antagonists | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142454-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | CSNK1A1, CSNK1E, CSNK1D | STAT3 523/4885HSD17B10 1649/4885GFER 4351/4885 |
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | IDO1, IDO2, INMT | STAT3 3230/4885HSD17B10 1417/4885GFER 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.